Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALOMA-3: Subcutaneous vs Intravenous Amivantamab with Lazertinib in EGFR-mutated NSCLC
NCT05388669Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Primary completion
- Jan 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of amivantamab in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Aug 2022; status: active, not recruiting.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05388669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05388669.